MA43816A - Protéines de liaison inductibles et méthodes d'utilisation - Google Patents

Protéines de liaison inductibles et méthodes d'utilisation

Info

Publication number
MA43816A
MA43816A MA043816A MA43816A MA43816A MA 43816 A MA43816 A MA 43816A MA 043816 A MA043816 A MA 043816A MA 43816 A MA43816 A MA 43816A MA 43816 A MA43816 A MA 43816A
Authority
MA
Morocco
Prior art keywords
inductible
methods
binding proteins
proteins
binding
Prior art date
Application number
MA043816A
Other languages
English (en)
French (fr)
Inventor
Patrick Baeuerle
Robert B Dubridge
Luke Evnin
Jeanmarie Guenot
Anand Panchal
Maia Vinogradova
Holger Wesche
Original Assignee
Maverick Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverick Therapeutics Inc filed Critical Maverick Therapeutics Inc
Publication of MA43816A publication Critical patent/MA43816A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043816A 2016-03-08 2017-03-08 Protéines de liaison inductibles et méthodes d'utilisation MA43816A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662305092P 2016-03-08 2016-03-08

Publications (1)

Publication Number Publication Date
MA43816A true MA43816A (fr) 2018-11-28

Family

ID=59789722

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043816A MA43816A (fr) 2016-03-08 2017-03-08 Protéines de liaison inductibles et méthodes d'utilisation

Country Status (14)

Country Link
US (1) US20180134789A1 (enExample)
EP (1) EP3426689A4 (enExample)
JP (3) JP7195927B2 (enExample)
KR (2) KR102501921B1 (enExample)
CN (1) CN109071667A (enExample)
AU (1) AU2017229687A1 (enExample)
BR (1) BR112018068189A2 (enExample)
CA (1) CA3016165A1 (enExample)
IL (1) IL261432B2 (enExample)
MA (1) MA43816A (enExample)
MX (1) MX2018010824A (enExample)
SG (1) SG11201807548SA (enExample)
TW (2) TW201808990A (enExample)
WO (1) WO2017156178A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
AU2016358296B2 (en) 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
BR112018073739A2 (pt) * 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteína de ligação de albumina sérica de domínio único
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109641046B (zh) 2016-05-20 2023-11-07 哈普恩治疗公司 单链可变片段cd3结合蛋白质
IL302917A (en) 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
JP6812551B2 (ja) 2016-11-23 2021-01-13 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原結合タンパク質
WO2018160671A1 (en) * 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Targeted checkpoint inhibitors and methods of use
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US20200115461A1 (en) * 2017-05-03 2020-04-16 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
MX2020002667A (es) 2017-09-08 2020-08-03 Maverick Therapeutics Inc Proteinas de unión condicionalmente activadas restringidas.
CN111315773A (zh) 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
EP3704151A4 (en) * 2017-11-01 2021-07-28 NantBio, Inc. EMT PATH BLOCKING IINTERLEUKIN 8 AND CONTROLLING CARCINOUS STEM CELLS
CN110218256B (zh) * 2018-03-02 2020-12-08 广西医科大学 抗CD3的纳米抗体CD3/Nb29及其制备方法与应用
CN110218253B (zh) * 2018-03-02 2020-12-04 广西医科大学 抗CD3的纳米抗体CD3/Nb14及其制备方法与应用
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
WO2019222283A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
WO2019222282A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
MX2020012252A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
US11634467B2 (en) 2018-06-22 2023-04-25 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
JP2021533744A (ja) 2018-08-09 2021-12-09 マベリック セラピューティクス, インコーポレイテッドMaverick Therapeutics, Inc. 条件的活性化型結合タンパク質を共発現及び精製するための方法
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
KR20210134091A (ko) * 2019-01-29 2021-11-08 그릿스톤 바이오, 인코포레이티드 다중특이적 결합 단백질
CN120484127A (zh) * 2019-03-05 2025-08-15 武田药品工业有限公司 受约束的条件性活化的结合蛋白
CN114173876A (zh) * 2019-03-05 2022-03-11 武田药品工业有限公司 含有靶向肿瘤抗原的Fc区和部分的条件性活化的结合蛋白质
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
WO2021097060A1 (en) * 2019-11-13 2021-05-20 Harpoon Therapeutics, Inc. Pro immune modulating molecule comprising a clustering moiety
WO2021097376A1 (en) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
KR20220115611A (ko) * 2019-12-13 2022-08-17 큐진 인크. 사이토카인-기반 생체활성 약물 및 이의 사용 방법
CN114829408B (zh) * 2019-12-20 2024-01-26 山东博安生物技术股份有限公司 用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂
AU2021208642B2 (en) * 2020-01-17 2025-06-05 Immunelogic Therapeutics, Inc. Pro-antibody that reduces off-target toxicity
CN114945597A (zh) * 2020-01-17 2022-08-26 艾提欧生物疗法有限公司 降低脱靶毒性的前抗体
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
KR20220166814A (ko) 2020-04-09 2022-12-19 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 항체를 함유하는 조성물
US12492252B2 (en) 2020-07-01 2025-12-09 Shandong Boan Biotechnology Co., Ltd. Anti-GPC3 antibody, anti-GPC3 chimeric antigen receptor and GPC3/CD3 bispecific antibody
WO2022006562A1 (en) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
CA3191431A1 (en) 2020-08-17 2022-02-24 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
AU2021329330A1 (en) * 2020-08-18 2023-02-02 Onchilles Pharma, Inc. Modified serine protease proproteins
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
MX2023006817A (es) 2020-12-09 2023-08-14 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
KR20230165798A (ko) 2021-04-06 2023-12-05 다케다 야쿠힌 고교 가부시키가이샤 제약된 조건부 활성화 결합 단백질을 사용한 치료 방법
US20240262917A1 (en) 2021-05-06 2024-08-08 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
WO2023034288A1 (en) 2021-08-31 2023-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
AU2022396272A1 (en) 2021-11-24 2024-06-06 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
CA3241395A1 (en) 2021-12-17 2023-06-22 Barbel SCHROFELBAUER Antibodies and uses thereof
US20250051755A1 (en) 2021-12-17 2025-02-13 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
JP2025528835A (ja) 2022-08-15 2025-09-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｓｌｎに対する抗体及びその使用方法
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
EP4619427A1 (en) * 2022-11-15 2025-09-24 F. Hoffmann-La Roche AG Recombinant binding proteins with activatable effector domain
WO2025237931A1 (en) * 2024-05-15 2025-11-20 F. Hoffmann-La Roche Ag Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2522586C (en) * 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
KR101229731B1 (ko) * 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
RU2013110876A (ru) 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
ME03440B (me) * 2011-05-21 2020-01-20 Macrogenics Inc Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
MX2014000031A (es) * 2011-07-01 2014-07-09 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos.
UA115781C2 (uk) * 2012-02-27 2017-12-26 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cx3cr1-зв'язуючий поліпептид
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150037334A1 (en) * 2012-03-01 2015-02-05 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
WO2014201021A2 (en) * 2013-06-10 2014-12-18 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells
EP3954713A3 (en) * 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
AU2016358296B2 (en) * 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
JP2021533744A (ja) * 2018-08-09 2021-12-09 マベリック セラピューティクス, インコーポレイテッドMaverick Therapeutics, Inc. 条件的活性化型結合タンパク質を共発現及び精製するための方法

Also Published As

Publication number Publication date
BR112018068189A2 (pt) 2019-02-05
KR20230041739A (ko) 2023-03-24
KR20180120245A (ko) 2018-11-05
SG11201807548SA (en) 2018-09-27
KR102501921B1 (ko) 2023-02-21
EP3426689A4 (en) 2020-01-15
IL261432B2 (en) 2024-03-01
RU2018134949A3 (enExample) 2020-08-14
US20180134789A1 (en) 2018-05-17
MX2018010824A (es) 2019-05-15
JP2022140856A (ja) 2022-09-28
IL261432B1 (en) 2023-11-01
AU2017229687A1 (en) 2018-09-20
TW202302631A (zh) 2023-01-16
TW201808990A (zh) 2018-03-16
EP3426689A1 (en) 2019-01-16
RU2018134949A (ru) 2020-04-08
JP7293456B2 (ja) 2023-06-19
JP7195927B2 (ja) 2022-12-26
JP2023123519A (ja) 2023-09-05
CN109071667A (zh) 2018-12-21
CA3016165A1 (en) 2017-09-14
JP2019513014A (ja) 2019-05-23
IL261432A (en) 2018-10-31
WO2017156178A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
MA43816A (fr) Protéines de liaison inductibles et méthodes d'utilisation
EP3442991A4 (en) RAS-BINDING PEPTIDES AND METHODS OF USE
EP3355920A4 (en) PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
EP3694529A4 (en) TRISPECIFIC PROTEINS AND METHOD OF USE
FR24C1033I2 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
EP3802581A4 (en) MULTISPECIFIC BINDING PROTEINS AND IMPROVEMENTS THERETO
IL281683A (en) Dll3 binding proteins and methods of use
MA47113A (fr) Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
EP3678731A4 (en) HEMOSTATIC VALVES AND METHOD OF USE
EP3684361A4 (en) SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3429591A4 (en) SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE
IL261666A (en) Related proteins and methods of using them
EP3655432A4 (en) BINDING PROTEINS 1
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
EP3393382A4 (en) OPHTHALMIC KNIFE AND METHOD OF USE
EP3317273A4 (en) EGFR HEMMER AND METHOD OF USE THEREOF
EP3402549A4 (en) MICRONADELE COMPOSITIONS AND METHOD FOR USE THEREOF
EP3423451A4 (en) INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING
EP3383431A4 (en) ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
EP3319611A4 (en) OXYSTEROLS AND METHOD OF USE THEREOF
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA44526A (fr) Oxystérols et leurs méthodes d'utilisation
EP3426298A4 (en) ILT7-BINDING MOLECULES AND METHOD OF USE THEREOF